FAHIM RAAFAT E F 4
4 · NABI BIOPHARMACEUTICALS · Filed Apr 5, 2010
Insider Transaction Report
Form 4
FAHIM RAAFAT E F
DirectorPresident, CEO and CFO
Transactions
- Other
Common Stock
[F1]2009-05-29$2.41/sh+5,404.282$13,000→ 278,414.659 total - Other
Common Stock
[F1]2009-11-30$2.41/sh+5,404.282$13,000→ 283,818.941 total - Award
Common Stock
[F2]2010-04-01+50,000→ 333,818.941 total - Award
Stock Option (Right to Buy)
[F3]2010-04-01+125,000→ 125,000 totalExercise: $5.49Exp: 2017-04-01→ Common Stock (125,000 underlying)
Footnotes (3)
- [F1]Voluntarily reported acquisition under the Issuer's 2000 Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3.
- [F2]Restricted Stock which vests in four equal annual installments beginning on April 1, 2011.
- [F3]The Option will become exercisable in four equal annual installments beginning on April 1, 2011.
Signature
James E. Dawson, as attorney-in-fact|2010-04-05